US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Moderna, Inc. - Common Stock (NQ:MRNA)

190.01 +1.07 (+0.57%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
What's going on in today's session: S&P500 most active stocks ↗
Via Chartmill
Which stocks are most active on Wednesday? ↗
Via Chartmill
News headline image
Pfizer Stock Rises Wednesday: What's Going On? ↗
Pfizer Inc (NYSE:PFE) shares are trading higher Wednesday, moving in sympathy with mRNA cancer vaccine-related companies after Merck & Co Inc (NYSE:MRK) and Moderna Inc (NASDAQ:MRNA) announced that... 
Via Benzinga
News headline image
Why Is Moderna (MRNA) Stock Rocketing Higher Today
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 144% in the afternoon session after its personalized mRNA cancer vaccine, develop... 
Via StockStory
Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session. ↗
Via Chartmill
Top S&P500 movers in Wednesday's pre-market session ↗
Via Chartmill
News headline image
Broadcom Drags the Nasdaq While the Dow and S&P 500 Climb ↗
Most stocks rose Wednesday, but a few big tech names told a different story. Here's what split the market again. 
Via The Motley Fool
Topics Stocks
News headline image
Moderna and Merck Just Made History With the First mRNA Cancer Vaccine to Succeed in a Phase 3 Trial. Here's What That Means for Investors. ↗
The treatment combines an mRNA shot with Merck's Keytruda. 
Via The Motley Fool
What's going on in today's session: S&P500 movers ↗
Via Chartmill
What's going on in today's session ↗
Via Chartmill
Which S&P500 stocks are gapping on Wednesday? ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Moderna (MRNA): Buy, Sell, or Hold Post Q2 Earnings?
What a fantastic six months it’s been for Moderna. Shares of the company have skyrocketed 44.2%, hitting $63.36. This was partly due to its solid quarterly r... 
Via StockStory
News headline image
3 Unprofitable Stocks We Keep Off Our Radar
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv... 
Via StockStory
Get insights into the top movers in the S&P500 index of Monday's pre-market session. ↗
Via Chartmill
News headline image
Moderna (MRNA) Q2 2026 Earnings Call Transcript ↗
Net loss improved 5% on international partnerships and manufacturing gains. 
Via The Motley Fool
Topics Earnings
Stay informed with the top movers within the S&P500 index on Friday. ↗
Via Chartmill
Top S&P500 movers in Friday's session ↗
Via Chartmill
What's going on in today's pre-market session: S&P500 movers ↗
Via Chartmill
News headline image
Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Prediction: These 2 Stocks Will Keep Winning No Matter What the Market Does ↗
These innovative biotech companies should reap the benefits of their breakthroughs. 
Via The Motley Fool
News headline image
MRNA Q2 Deep Dive: Pipeline Progress and Seasonal Vaccine Dynamics Shape Outlook
Biotechnology company Moderna (NASDAQ:MRNA) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 2.1% year on year to $145 mi... 
Via StockStory
News headline image
Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Q2 Earnings Call Highlights ↗
Moderna (NASDAQ:MRNA) reported second-quarter revenue of $145 million, exceeding the high end of its prior guidance range, while continuing to reduce costs and advance programs spanning respiratory... 
Via MarketBeat
Topics Earnings
Get insights into the top movers in the S&P500 index of Friday's pre-market session. ↗
Via Chartmill
News headline image
Moderna (NASDAQ:MRNA) Beats Expectations in Q2 CY2026
Biotechnology company Moderna (NASDAQ:MRNA) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 2.1% year on year to $145 m... 
Via StockStory
News headline image
Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna (MRNA) Q2 Earnings: What To Expect
Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results this Friday before market hours. Here’s what investors should know. Moderna b... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Healthcare Stock to Keep an Eye On and 2 We Avoid
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >